SAN JOSE, Calif. & OSAKA, Japan (BUSINESS WIRE) Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX1.
An implant that treats patient pain following knee surgery for up to three weeks relies on biodegradable polymers from Evonik to expand drug-delivery window.
Firm also plans to develop purpose-built innovation district with life sciences infrastructure and specialised facilities. Read more at straitstimes.com.